

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A






FIG. 3B

00095749, 002700



Log conc. SA-peptide complex

FIG. 3C



Log conc. SA-peptide complex

FIG. 3D

00003760-0002706




FIG. 3E




FIG. 3F



0083768.022702




FIG. 4A

[illegible]

Applicant(s): DOWER et al.
Serial No.: To be assigned
Attorney: Virginia C. Bennett
Telephone: (919) 483-1012
Sheet 10 of 15

[illegible]

FIG. 5A

pELM3/pELM15 after subcloning of library insert:

FIG. 5B

FIG. 5B





FIG. 6A



BALB/c mice were treated with carboplatin (125 mg/kg) on Day 0.

Dashed lines represent female mice.

Solid lines represent male mice.

Bold line represents data published by Ulich, T. R., et al. Blood 66(3):971-976, 1995.

FIG. 7

Carboplatin-induced Thrombocytopenia in Normal Mice:
Single-dose Titration (mg/kg)





FIG. 8

Amelioration of Carboplatin-induced Thrombocytopenia by AF12513 (Day 10)



Carboplatin (CBP; 125-50 mg/kg, ip) was given on Day 0.
 AF12513 (513; 1 mg/kg, ip) was given on Days 1-9.

* p= <0.05

FIG. 9